Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix hexa primary infant vaccination study with comparator vaccines
2013-004304-19Phase 3
- Sponsor
- GSK
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pertussis filamentous haemagglutinin, Bordetella pertussis toxoid antigen (glutaraldehyde inactivated), haemophilus influenzae type b vaccine, Hepatitis B vaccine, pneumococcal 7-valent conjugate vaccine and 2 more in diphtheria, Tetanus, pertussis and 5 more (2 arms), sponsored by GSK. Primary endpoint: Primary immunogenicity endpoint.
02
Drugs
pertussis filamentous haemagglutininBordetella pertussis toxoid antigen (glutaraldehyde inactivated)haemophilus influenzae type b vaccineHepatitis B vaccinepneumococcal 7-valent conjugate vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2013-004304-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004304-19.